Evidence map›Paper›PMID 40526100›Full record

ArticleOncotarget2025

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.

Fei Fei, Milhan Telatar, Vanina Tomasian, Lisa Chang, Olga Danilova, Javier Arias-Stella, Raju Pillai, Lorinda Soma, Parastou Tizro, Pamela S Becker and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fei FeiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Milhan TelatarDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Vanina TomasianDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Lisa ChangDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Olga DanilovaDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Javier Arias-StellaDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Raju PillaiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Lorinda SomaDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Parastou TizroDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Pamela S BeckerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Anthony S SteinDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poorly characterized molecular features. To identify disease-specific mutational profiles, we performed targeted next-generation sequencing (NGS) on a cohort of 21 BPDCN patients. Our study revealed that

Indexed as

Dendritic CellsHematologic NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorBlastic Plasmacytoid Dendritic Cell NeoplasmDioxygenasesDNA-Binding ProteinsDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationBiomarkers, TumorDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanBlastic plasmacytoid dendritic cell neoplasm (BPDCN)CCDC50Next-generation sequencing (NGS)

Identifiers

PMID40526100
PMCPMC12173198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.